Managing Diabetes is Now Simpler and More Convenient with New Premixed Insulin Analogue
- Available in Canada, NovoMix 30 Helps Patients Achieve Blood
Glucose Control -
CALGARY, Alberta, April 3, 2007 /CNW/ - Canadians with
diabetes now have a new treatment option, which controls blood
glucose throughout the day and helps to simplify and improve the
management of the disease. (1)(2) Now available in Canada,
NovoMix(R) 30 (biphasic insulin aspart) is a premixed insulin
analogue indicated for adults affected by diabetes that is a great
option for people who are having difficulty controlling their blood
sugar using human insulin or anti-diabetic pills, or are just
starting to use insulin.
Diabetes is an epidemic in this country that affects more than two
million Canadians. Ninety per cent of these people have type 2
diabetes.(3) Diabetes is a serious condition that needs to be
managed throughout a lifetime. There is no cure, so using newer
types of insulin that more closely mimic the body's own insulin can
help Canadians affected by diabetes achieve long-term health. If
left untreated or poorly managed, diabetes can lead to heart
disease, kidney disease and blindness.(4)
"Many people with diabetes believe that their blood glucose is well
controlled when this may not be the case. Often they start taking
insulin later than they should, which can lead to serious long-term
complications," said Dr. Stuart Ross, Clinical Professor of
Medicine at the University of Calgary. NovoMix(R) 30 helps simplify
the management of diabetes care because it combines a rapid-acting
and long-acting insulin into one dose, and it has also been shown
to help people with diabetes achieve recommended blood glucose
targets."
In addition to long-term complications, people with diabetes also
worry about side effects like dizziness and disorientation that can
occur when their blood glucose is too low or they have too much
insulin. These types of effects are less likely with insulin
analogues like NovoMix(R) 30.(5)
People with diabetes take insulin because their bodies are unable
to produce insulin, or enough insulin, needed to manage blood
sugar. NovoMix(R) 30 contains two components -- a long-lasting
insulin and a rapid-acting insulin analogue that starts to work in
10 minutes -- in one dose. This premixed combination closely mimics
the body's own insulin by providing a rapid initial blood glucose
lowering effect needed right at mealtimes, followed by a prolonged
effect that controls blood glucose throughout the day.
"Insulin has been very effective in helping me manage my diabetes,
but I currently have to take insulin every night before bed, and at
least 30 minutes before every meal, which can be hit and miss
especially when I eat out," said Salma Ladak, who has been living
with diabetes for more than 25 years. "The
availability of NovoMix(R) 30 means I can more easily control my
blood sugar with a less rigid schedule, and less worry about blood
sugar lows. It will make a significant difference in the way I feel
about my diabetes."
Type 2 Diabetes
More than two million Canadians have diabetes, and this number is
expected to rise to more than three million by the end of the
decade.(6) Type 2 diabetes is the most common, affecting
approximately 90 per cent of Canadians with the disease.(7)
Diabetes can lead to serious health complications, including
increased risk of heart disease, stroke, kidney disease, blindness,
and amputation.(8) The cost of diabetes to Canadian society is
expected to rise to $19.2 billion by 2020.(9)
Lifestyle changes, including healthy eating and physical activity,
can prevent or delay the onset of type 2 diabetes.(10)
NOVO NORDISK CANADA INC.
Novo Nordisk is a healthcare company and a world leader in
diabetes care and biopharmaceuticals. Novo Nordisk manufactures and
markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. Novo Nordisk's business is driven by the Triple Bottom
Line: a commitment to economic success, environmental soundness,
and social responsibility to employees and customers.
The company's 80-year history of diabetes care innovation and
achievement originated in Canada where insulin was discovered. With
headquarters in Denmark, Novo Nordisk has more than 23,500
full-time employees in 79 countries, and markets its products in
179 countries. Novo Nordisk's B shares are listed on the stock
exchanges in Copenhagen and London. Its ADRs are listed on the New
York Stock Exchange under the symbol 'NVO'. For more information,
visit www.novonordisk.com.
A VNR will be available at 11:00 and 14:30 EST at the following
coordinates:
11:00 - 11:30 and 14:30-15:00
Eastern
Anik F2, C-Band, Transponder 1B @111.1
West
Vertical Polarization, D/L Freq. 3740MHz.
Channel 2
Audio subcarriers 6.8 left, 6.2 right
<<
---------------------------------------------------
(1) Boehm B, et al.
European Journal of Internal Medicine 2004;15:496
(2) Raskin P, Allen E,
Hollander P, et. al. Initiating Insulin Therapy
in Type 2 Diabetes: A comparison of biphasic and basal
insulin
analogs. Diabetes Care 2005; 28.
(3) Canadian Diabetes
Association. The Prevalence and costs of
Diabetes. Available at:
http://www.diabetes.ca/Section_About/prevalence.asp.
Accessed on: January 16, 2007.
(4) Ibid
(5) Boehm B, et al.
European Journal of Internal Medicine 2004;15:496
(6) Canadian Diabetes
Association. The Prevalence and costs of
Diabetes. Available at:
http://www.diabetes.ca/Section_About/prevalence.asp.
Accessed on: January 16, 2007.
(7) Canadian Diabetes
Association. Diabetes Facts. Available at:
http://www.diabetes.ca/Section_About/thefacts.asp.
Accessed on:
January 16, 2007.
(8) Canadian Diabetes
Association. The Prevalence and costs of
Diabetes. Available at:
http://www.diabetes.ca/Section_About/prevalence.asp.
Accessed on: January 16, 2007.
(9) Ibid
(10) Canadian Diabetes
Association. Diabetes Facts. Available at:
http://www.diabetes.ca/Section_About/thefacts.asp.
Accessed on: January 16, 2007.
>>
-30-
/For further information: Dana Allison, Jennifer Goode, Edelman,
(416)
979-1120, ext. 318, 230, Dana.Allison@edelman.com,
Jennifer.Goode@edelman.com/
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
